Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMP: Phase 3 NVK-002 (low-dose atropine) in children with myopia
2018-001077-24Phase 3Completed
- Sponsor
- Vyluma
- Start
- May 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of NVK002 in myopia, sponsored by Vyluma. Started May 2018; status: completed.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on 2018-001077-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001077-24.